The New England Journal of Medicine has published findings from a major phase 3 trial testing a newer type of drug for patients whose multiple myeloma has stopped responding to previous treatment.
The trial, called MajesTEC-3, examined whether teclistamab — a bispecific antibody (a laboratory-made protein designed to attach to two targets at once) — improves survival and disease control in patients with relapsed or refractory multiple myeloma (blood cancer that has returned or stopped responding to treatment). The drug works by targeting two proteins: B-cell maturation antigen, found on myeloma cells, and CD3, found on immune cells, effectively directing the body’s own defences to attack the cancer.
According to the NEJM, whether teclistamab actually improves outcomes in this patient group remained unclear going into the trial — making these phase 3 results a significant step in establishing the evidence base. The journal has summarised the findings in a Quick Take video alongside the full publication.
Multiple myeloma is a cancer of plasma cells in the bone marrow. Patients whose disease relapses or stops responding to standard treatments have limited options, so trials in this area are closely watched by haematology specialists.
The findings are from a phase 3 trial — the stage of clinical research that tests a treatment in large numbers of patients before regulators consider approval.
Kent residents living with multiple myeloma, or those supporting someone who is, should speak to their haematology team or GP about what current treatment options are available to them. NHS 111 can also provide guidance on accessing specialist services.
Key information
- Speak to your GP or hospital specialist if you have questions about myeloma treatment options
- NHS 111 (call 111 or use the online service) can help you find the right care
- Macmillan Cancer Support helpline: 0808 808 00 00, available Monday to Friday, 8am to 6pm
Source: @NEJM